ImmunoPrecise Antibodies (IPATF) Stock Price, News & Analysis

Company Overview

ImmunoPrecise Antibodies Ltd. engages in the provision of human therapeutic antibody discovery and development services. It offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. Its services include B cell sorting, screening and sequencing; custom, immune and naive phage display production and screening; bi-specific, tri-specific, VHH, and VNAR antibody manufacturing; antibody engineering; and antibody optimization and humanization. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.

Key Stats

• Today's Range: $1.08 to $1.31
• 50-Day Range: $0.45 to $1.31
• 52-Week Range: $1.15 to $20.25
• Volume: 2.71 million shs
• Average Volume: 20,327 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IPATF Stock Analysis - Frequently Asked Questions

How have IPATF shares performed this year?

ImmunoPrecise Antibodies' stock was trading at $0.41 at the beginning of the year. Since then, IPATF shares have increased by 219.5% and is now trading at $1.31.

How do I buy shares of ImmunoPrecise Antibodies?

Shares of IPATF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:IPATF
• CIK: N/A
• Web: www.immunoprecise.com
• Phone: (250) 483-0308
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A